Access cutting-edge wet macular degeneration treatment through this clinical trial at a research site in Springfield. Study-provided care at no cost to qualified participants.
Access wet macular degeneration specialists in Springfield at no cost
This study follows strict safety protocols and ethical guidelines
All study-related wet macular degeneration treatment provided free
RGX-314 is being developed as a potential novel one-time gene therapy treatment for the treatment of neovascular (wet) age related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for tre
Sponsor: AbbVie
Check if you qualify for this wet macular degeneration clinical trial in Springfield, IL
If you're searching for wet macular degeneration treatment options in Springfield, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Springfield research site is actively enrolling participants for this clinical trial. You'll receive care from experienced wet macular degeneration specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.